FCCC LOGO Faculty Publications
Ramirez UD , Nikonova AS , Liu H , Pecherskaya A , Lawrence SH , Serebriiskii IG , Zhou Y , Robinson MK , Einarson MB , Golemis EA , Jaffe EK
Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization
BMC Cancer. 2015 May 28;15 :436
PMID: 26016476    PMCID: PMC4451962    URL: https://www.ncbi.nlm.nih.gov/pubmed/26016476
Back to previous list
Abstract
BACKGROUND: Overexpression or mutation of the epidermal growth factor receptor (EGFR) potently enhances the growth of many solid tumors. Tumor cells frequently display resistance to mechanistically-distinct EGFR-directed therapeutic agents, making it valuable to develop therapeutics that work by additional mechanisms. Current EGFR-targeting therapeutics include antibodies targeting the extracellular domains, and small molecules inhibiting the intracellular kinase domain. Recent studies have identified a novel prone extracellular tetrameric EGFR configuration, which we identify as a potential target for drug discovery. METHODS: Our focus is on the prone EGFR tetramer, which contains a novel protein-protein interface involving extracellular domain III. This EGFR tetramer is computationally targeted for stabilization by small molecule ligand binding. This study performed virtual screening of a Life Chemicals, Inc. small molecule library of 345,232 drug-like compounds against a molecular dynamics simulation of protein-protein interfaces distinct to the novel tetramer. One hundred nine chemically diverse candidate molecules were selected and evaluated using a cell-based high-content imaging screen that directly assessed induced internalization of the EGFR effector protein Grb2. Positive hits were further evaluated for influence on phosphorylation of EGFR and its effector ERK1/2. RESULTS: Fourteen hit compounds affected internalization of Grb2, an adaptor responsive to EGFR activation. Most hits had limited effect on cell viability, and minimally influenced EGFR and ERK1/2 phosphorylation. Docked hit compound poses generally include Arg270 or neighboring residues, which are also involved in binding the effective therapeutic cetuximab, guiding further chemical optimization. CONCLUSIONS: These data suggest that the EGFR tetrameric configuration offers a novel cancer drug target.
Notes
Ramirez, Ursula D Nikonova, Anna S Liu, Hanqing Pecherskaya, Anna Lawrence, Sarah H Serebriiskii, Ilya G Zhou, Yan Robinson, Matthew K Einarson, Margret B Golemis, Erica A Jaffe, Eileen K England BMC Cancer. 2015 May 28;15:436. doi: 10.1186/s12885-015-1415-6.